Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 26 January 2026 - 16:12

Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Date of authorisation: 11/05/1998, Revision: 50, Status: Authorised

Submitted by Anonymous (not verified) on 26 January 2026 - 16:00

Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Date of authorisation: 11/05/1998, Revision: 50, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 February 2026, 15:00 (CET) to 23 February 2026, 17:00 (CET)

Submitted by Anonymous (not verified) on 26 January 2026 - 15:48

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 February 2026, 15:00 (CET) to 23 February 2026, 17:00 (CET)

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 January 2026, 13:30 (CET) to 30 January 2026, 15:30 (CET)

Submitted by Anonymous (not verified) on 26 January 2026 - 15:46

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - January 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 January 2026, 13:30 (CET) to 30 January 2026, 15:30 (CET)

Human medicines European public assessment report (EPAR): Enurev Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 26 January 2026 - 15:45

Human medicines European public assessment report (EPAR): Enurev Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Tovanor Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 26 January 2026 - 15:44

Human medicines European public assessment report (EPAR): Tovanor Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Seebri Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 26 January 2026 - 15:43

Human medicines European public assessment report (EPAR): Seebri Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Zynyz, retifanlimab, Date of authorisation: 19/04/2024, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 26 January 2026 - 15:18

Human medicines European public assessment report (EPAR): Zynyz, retifanlimab, Date of authorisation: 19/04/2024, Revision: 1, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness